SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001867096-24-000103
Filing Date
2024-06-05
Accepted
2024-06-05 16:18:11
Documents
1
Period of Report
2024-06-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1717618682.html 4  
1 FORM 4 wk-form4_1717618682.xml 4 4209
  Complete submission text file 0001867096-24-000103.txt   5647
Mailing Address C/O XERIS PHARMACEUTICALS 180 N. LASALLE ST., STE. 1800 CHICAGO IL 60601
Business Address
HALKUFF DAWN (Reporting) CIK: 0001743658 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 241022227

Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)